Ingenuity and Geospiza will integrate their Ingenuity Pathway Analysis and GeneSifter software products to create a research workflow for next-generation sequence data analysis and visualization, Ingenuity said this week.
Ingenuity's Chief Scientific Officer and Chief Technology Officer Doug Basset said the partnership aims to help joint customers answer research questions by "providing a streamlined way for researchers to move from a list of genes, isoforms, or variants all the way to identifying drug targets, validating biomarkers, generating hypotheses, and understanding drug mechanism of action."
The partners hope that the combined tools will speed up drug discovery and –omics research by enabling researchers to "visualize their data in the context of known biological processes, functions, diseases, pathways and relationships," said Geospiza Chief Technology Officer Todd Smith.
Ingenuity recently merged IPA with California-based TransMed Systems' XB Bio-Integration Suite — a data analytics and management tool that lets users capture, analyze, visualize, and share their genomic data as well as access multiple genomic data sources, create patient cohorts, and generate hypotheses
The combined platform is expected to enable users to collect and analyze pre-clinical and clinical data in the context of signaling and metabolic pathways, networks, and cellular processes that are available in IPA (BI 10/22/2010).